A gE/gI/US9-triple deletion inactivated vaccine provides complete protection against emerging PRV variant infection Authors: Yuchuan Yang, Ziyun Xie, Heteng Zhang, Zhihua Yang, Baishi Lei, Kuan Zhao, Yunhang Zhang, Wanzhe Yuan, Jie Tong, Wuchao Zhang Published: 2026 ABSTRACT AbstractSince 2011, pseudorabies virus (PRV) variant strains have emerged in China, against which conventional vaccines confer inadequate protection, resulting in substantial economic losses. Consequently, there is an urgent need to develop a novel vaccine capable of effectively addressing this challenge. Here, the homology-directed repair (HDR)-CRISPR/Cas9 technology was employed to specifically target and knockout the gI, gE, and US9 genes, which were further developed into inactivated vaccines. Subsequently, these three recombinant viruses, along with a previously constructed gE/gI/US9/US2 deleted strain, were systematically evaluated. In vitro analysis revealed that all mutants exhibited viral titers and growth kinetics comparable to the parental strain but formed smaller plaques. No genetic reversion was detected after 20 passages, confirming favorable genetic stability. In animal studies, the gE/gI/US9 triple-gene deletion mutant induced stronger gB-specific and neutralizing antibodies, enhanced Th1 cytokine secretion (IFN-γ, TNF-α), and promoted lymphocyte proliferation, without altering Th2 cytokines (IL-6, IL-4). Additionally, all three inactivated virus-immunized groups achieved complete protective efficacy, surpassing the 80% protection rate observed with a commercial inactivated vaccine. Notably, the triple-gene deletion group experienced less weight loss, had a lower brain and lung viral load following the challenge. In conclusion, this study identified the triple-gene deletion strain rPRV ΔgE/gI/US9 as a highly promising inactivated vaccine candidate, offering a novel strategy for PRV prevention and control.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12917-026-05592-8.Keywords: Pseudorabies virus, gE/gI/US9, Gene deletion, Immunogenicity, Inactivated vaccine candidate Introduction Pseudorabies (PR), also known as Aujeszky’s disease (AD), is an acute infectious disease caused by the pseudorabies virus (PRV) [1]. Although vaccination remains the primary strategy for PR control and the Bartha-K61 vaccine had been highly effective since its introduction in the 1990s, the livestock industry has faced significant challenges since 2011 due to the emergence of PRV variant strains [2]. Critically, these emerging variants have demonstrated not only significantly increased virulence [3] but also the ability to break through Bartha-K61 vaccine-induced immunity [4], leading to frequent PR outbreaks in vaccinated herds [5] and consequently inflicting substantial economic losses on the swine industry. In terms of current vaccine development and application, existing prevention and control strategies still face notable limitations. While attenuated live vaccines offer strong immunogenicity [6], they carry risks such as genetic instability and potential reversion to virulence [7]. In contrast, inactivated vaccines are safer [8], as they eliminate these risks, but they generally induce weaker immune responses [9], often requiring multiple booster doses to achieve sustained protection. Therefore, urgent action is needed to develop more efficient inactivated vaccines. These vaccines can address challenges from evolving PRV strains and mitigate long-term economic impacts on the swine industry. The PRV gE protein plays a critical role in viral virulence and typically forms a dimer with the gI protein, creating a type I membrane glycoprotein with a large extracellular domain [10]. Previous studies have demonstrated that the deletion of the gE/gI complex can enhance virus titers and provide a molecular marker for distinguishing wild-type PRV infections from vaccine strain infections, thus offering an essential tool for PRV purification [11]. Additionally, research on the PRV US9 protein has revealed that US9 is a key effector in the anterograde axonal transport process of PRV, forming the core mechanism of this transport system [12]. The US9 protein, as a type II transmembrane protein, synergizes with the gE/gI dimer to facilitate viral spread within the host and neuronal tissues [10]. Further investigations indicate that US9 deletion significantly reduces virus titers and may compromise UL16 protein stability [13], a protein involved in redox reactions or cellular apoptosis [14]. Studies on the US2 protein show that its deletion not only increases virus titers but also enhances viral pathogenicity in mice [15]. Based on these findings, this study was designed to systematically assess a panel of PRV mutants with progressively more complex deletions and to evaluate the critical trade-offs between viral titer and vaccine immunogenicity to guide the rational design of a next generation vaccine. In this study, we utilized the CRISPR/Cas9 system to generate PRV mutant strains with single (rPRV ΔgE), double (rPRV ΔgE/gI), and triple gene deletions (rPRV ΔgE/gI/US9). These mutants were further compared with a previously laboratory constructed quadruple gene deletion virus (rPRV ΔgE/gI/US9/US2). By systematically analyzing the impact of different gene deletions on viral characteristics, we aimed to identify candidate vaccine strains with improved immunogenicity. Using a mouse model, we performed a comprehensive evaluation of the four mutant strains to assess their potential efficacy as vaccine candidates. The findings of this study provide a critical theoretical and experimental basis for the development of more efficient inactivated PRV vaccines. Materials and methods Cell, viruses and animals Vero cells were routinely maintained in high-glucose Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and incubated in a humidified atmosphere at 37 °C with 5% CO₂. Mycoplasma testing for all cell lines yielded negative results. The classic PRV Fa strain and variant SH15 strain (GenBank accession No. PV360712.1) were preserved in our laboratory. The commercially available vaccine is an inactivated, US8 gene-deleted strain approved for use in China. Six-week-old female KM mice were procured from SiPeiFu Biotechnology Co., Ltd. (Beijing, China). Mice were housed in cages with corncob bedding under a healthy, controlled environment with stable temperature, and the study was performed in accordance with Laboratory Animal Guidelines for Euthanasia (GB/T 39760 − 2021). Each mouse received an intraperitoneal injection of pentobarbital sodium at 100 mg/kg body weight, with the injection volume adjusted by body weight. After injection, the corneal reflex, respiratory rate, and limb movement were continuously monitored. Once fully unconscious, euthanasia was performed via eyeball enucleation and exsanguination to ensure a painless death. Construction of three PRV gene-deletion strains: gE, gE/gI, gE/gI/US9 rPRV ΔgE-EGFP was constructed using the CRISPR/Cas9 system. Specifically, two single-guide RNAs (sgRNAs) targeting the US8-EGFP insertion sequence were designed with the assistance of an online tool (https://crispor.gi.ucsc.edu/) and subsequently cloned into the pX335 vector via Bbs I digestion, followed by verification by sequencing, resulting in the construct named US8-EGFP-sgRNA-1 and US8-EGFP-sgRNA-2. Based on viral DNA sequences and EGFP plasmids, donor sequences were constructed using overlapping PCR technology. Thereafter, 2 µg of PRV SH15 genomic DNA, 2 µg of donor DNA template, and 1 µg of each pX335 plasmid with sgRNA1 and sgRNA2 targeting SH15 US8-EGFP were co-transfected into Vero cells using Lipofectamine 2000 Reagent (Invitrogen, Carlsbad, CA, USA). Following the observation of a pronounced cytopathic effect (CPE) induced by PRV, the cultures were harvested and subjected to five rounds of plaque purification. After each passage, a single plaque was selected, and the deletion of the gE, and EGFP genes was confirmed by PCR analysis. The primers and sgRNA sequences used are listed in Tables 1 and 2. Other recombinant viruses were also generated using a similar method. The final recombinant viruses with deletions of gE, gE/gI and gE/gI/US9 were designated as rPRV ΔgE, rPRV ΔgE/gI, and rPRV ΔgE/gI/US9. Table 1Single guide RNAs (sgRNAs) used in this studyPrimerPrimer sequence (5’-3’)DetailssgRNA-gE-EGFP-5’FCACCGCCCGCGAGTCTCGCACACACsgRNA-gE-EGFP-FsgRNA-gE-EGFP-5’RAAACGTGTGTGCGAGACTCGCGGGCsgRNA-gE-EGFP-3’FCACCGCGCCCGCATTCCGACATGCCsgRNA-gE-EGFP-RsgRNA -gE-EGFP-3’RAAACGGCATGTCGGAATGCGGGCGCsgRNA-gE-5’FcaccgCCTGGGCACCCCCGCGAGTCsgRNA-gE-FsgRNA-gE-5’RaaacGACTCGCGGGGGTGCCCAGGcsgRNA-gE-3’FcaccgAGCATTTTTTTCACTGCGCCsgRNA-gE-RsgRNA-gE-3’RaaacGGCGCAGTGAAAAAAATGCTcsgRNA-gI-5’FcaccgGTCCGTAGCCTCCGCAGTACsgRNA-gI-FsgRNA-gI-5’RaaacGTACTGCGGAGGCTACGGACcsgRNA-US9-3’FcaccgGTAGCGAGCGAGCGAGCGACsgRNA-US9-RsgRNA-US9-3’RaaacGTCGCTCGCTCGCTCGCTACc Single guide RNAs (sgRNAs) used in this study Table 2Donor amplification primers used in this studyPrimerPrimer sequence (5’-3’)DetailsgE-EGFP5’-FCGTCGCCGCCCGCGGACGAGTGCCgE-EGFP-LgE-EGFP5’-RTTAATAACTAGGTCTCAACCCCGACTCGCGGGGGTEGFP-FGGTTGAGACCTAGTTATTAATAGTAATCAATTACEGFPEGFP-RCTCCCGGTATGCAGTGAAAAAAATGCTTTATTTGgE-EGFP3’-FTTTTCACTGCGCCCGGCGCCGCCTCCGTCGACATgE-EGFP-RgE-EGFP3’-RCGTAGCACCACTCGGTGAGCACCTgE5’-FGCTGGAGCGACGACAGCTTCAAGCgE-LgE5’-RGGCGCCGGGCCTGCGGAGGCTACGGACCGGGCTGCgE3’-FGCCTCCGCAGGCCCGGCGCCGCCTCCGTCGACATGgE-RgE3’-RCGTAGCACCACTCGGTGAGCACCTgE/gI5’-FGCTGGAGCGACGACAGCTTCAAGCgI-LgE/gI5’-RGGCGCCGGGCCTGCGGAGGCTACGGACCGGGCTGCgE/gI3’-FGCCTCCGCAGGCCCGGCGCCGCCTCCGTCGACATGgI-RgE/gI3’-RCGTAGCACCACTCGGTGAGCACCTgE/gI/US9-5’-FGCTGGAGCGACGACAGCTTCAAGCUS9-LgE/gI/US9-5’-RGCTCCCGGTCCTGCGGAGGCTACGGACCGGGCTGCgE/gI/US9-3’-FCTCCGCAGGACCGGGAGCGGGGGCCCGCCCCCAUS9-RgE/gI/US9-3’-RTCAGGACGGACGACCACTCCGTGT Donor amplification primers used in this study Detection of the biological characteristics of PRV In order to investigate the growth kinetics of the virus, Vero cells cultured in 6-well plates were infected with PRV SH15, rPRV ΔgE, rPRV ΔgE/gI, rPRV ΔgE/gI/US9 and rPRV ΔgE/gI/US9/US2 at a multiplicity of infection (MOI) of 0.01 for 1 h at 37 °C. Following incubation, the inoculum was discarded, and the cells were treated with 0.3 M citric acid (pH 3.0) to inactivate residual extracellular virus, followed by three washes with PBS. Subsequently, the cells were maintained in DMEM supplemented with 2% FBS for further culture. At 0, 4, 8, 12, 24, 36, 48, 60, and 72 h post-infection, cell samples were harvested, and the viral titers were determined using the Reed-Muench method, and expressed as the 50% tissue culture infectious dose (TCID50). To assess the plaque size induced by PRV mutants. Vero cells were grown as monolayers and then infected with PRV SH15, rPRV ΔgE, rPRV ΔgE/gI, rPRV ΔgE/gI/US9, and rPRV ΔgE/gI/US9/US2 strains and overlaid with DMEM containing 2% FBS and 1% methylcellulose. The cultures were then incubated at 37 °C under 5% CO2 for 96 h. Plaques were subsequently stained with crystal violet and their sizes quantitatively analyzed using ImageJ software (National Institutes of Health, Bethesda, MD, USA). Additionally, to confirm the genetic stability of the different PRV strains, recombinant viruses were passaged 20 times in Vero cells. Viral DNA was extracted every 5 passages, and the gE, gI, and US9 genes were amplified using specific primers. The primers sequences used are listed in Table 3. Table 3Detection primers used in this studyPrimerPrimer sequence (5’-3’)DetailsgI-US9-FGCGTGTGCGTCTACATCTTCIdentify thedeleted genesgI-US9-RgcggtggagaagaagagtccgE-q-FGGGACACGTTCGACCTGATGqPCRgE-q-RTGGTAGATGCAGGGCTCGTA Detection primers used in this study Identify the deleted genes Preparation of vaccines PRV mutants (108 TCID50/mL) were chemically inactivated by treatment with 0.05% (v/v) β-propiolactone (BPL) at 4 °C for 24 h. To ensure complete hydrolysis of residual BPL and removal of its potential toxicity, the inactivated solution was subsequently incubated at 37 °C for 30 min. The efficacy of inactivation was confirmed by inoculating the treated virus stock into Vero cells, with no CPE observed. The PRV vaccine formulation was prepared by mixing an equal volume of the inactivated virus with ISA206 adjuvant (Seppic, Paris, France). The commercial PRV vaccine employed as a control was an inactivated vaccine from Pulike Biological Engineering, Inc., which was also formulated with ISA206 adjuvant. Vaccine efficacy experiment Ninety 6-week-old female SPF KM mice were randomly divided into 6 groups with 15 mice per group. Mice in Group A were intramuscularly inoculated with 200 µL DMEM, and designated as the positive control for the subsequent viral challenge; Group B (blank control) received no treatment; Group C, Group D, Group E, and Group F were intramuscularly vaccinated with 200 µL (107 TCID50) of rPRV ΔgE, rPRV ΔgE/gI, rPRV ΔgE/gI/US9, and rPRV ΔgE/gI/US9/US2, respectively. At 14 days post immunization (dpi), a booster immunization with the same dose was administered. On 21 dpi, five mice (n = 5) from each group were euthanized, and serum was collected to measure the levels of specific gB antibodies and neutralizing antibodies. Simultaneously, splenocytes were isolated for assessing cell proliferation capacity and cytokine secretion profiles. The remaining mice (n = 10) were challenged with the PRV SH15 strain (105 TCID50 per mouse) via intramuscular injection. During the experiment, clinical signs and body weight changes were monitored daily over a 14-day observation period. On 14 days post challenge (dpc), brain, lung, and spleen tissue samples were harvested from surviving mice in each group for viral load quantification or histopathological evaluation. Detection of serological antibodies The specific gB antibody levels in the serum were quantitatively evaluated using a commercial PRV gB antibody detection kit (Green Spring, Shenzhen, China). The experiment was operated in accordance with the standard enzyme-linked immunosorbent assay (ELISA) procedure. HRP-labeled goat anti-mouse IgG (Solarbio, Beijing, China) was used as the secondary antibody, and then OD450 values were detected by microplate reader. The results were expressed as the S/N ratio, with serum samples defined as positive for gB-specific antibodies when the S/N ratio was ≥ 0.2 and negative when the S/N ratio was < 0.2. Detection of neutralizing antibodies Serum samples were collected on 21 and 35 dpi. The samples were heat-inactivated at 56 °C for 30 min. Subsequently, the serum was serially diluted twofold and incubated with 100 TCID50 of either the PRV SH15 or Fa strain under conditions of 37 °C and 5% CO2 for 1 h. The mixture was then transferred to Vero cell monolayers in 96-well culture plates, and the CPE was observed and recorded. The neutralizing antibody titer was finally calculated using the Reed-Muench method. Lymphocyte proliferation response Each group of mice (n = 5) was euthanized on the 21dpi. Spleens were aseptically harvested, homogenized, and filtered through a 70-µm cell strainer to obtain single-cell suspensions. To lyse erythrocytes, the samples were treated with erythrocyte lysis buffer (Solarbio, Beijing, China) on ice for 5 min. The resulting splenocyte suspension was resuspended in RPMI 1640 medium supplemented with 10% FBS (containing 100 IU/mL penicillin and 100 µg/mL streptomycin). Following cell counting, 50 µL of splenocytes at a concentration of 1 × 106 cells/mL were seeded into 96-well plates. Subsequently, the splenocytes were stimulated with 50 µL of Con A (5 µg/mL), heat-inactivated PRV antigen (5 × 106 TCID50/mL) or RPMI 1640 medium as a control. After 48 h of incubation, 10 µL of CCK-8 reagent (Solarbio, Beijing, China) was added to each well, followed by an additional 4 h incubation. The stimulation index (SI) was calculated as the ratio of the OD value in the stimulated well to that in the unstimulated well. Measurements of IL-4, IL-6, INF-γ and TNF-α by splenocytes in vitro Spleen cells (1 × 106 cells/mL) were seeded at 2 mL per well in 6-well plates and re-stimulated with inactivated PRV antigen (5 × 105 TCID50) under culture conditions of 37 °C and 5% CO₂ for 48 h. The cell suspension was then centrifuged at 1500 rpm for 5 min. Following the manufacturer’s instructions, the concentrations of IL-4, IL-6, IFN-γ and TNF-α in the supernatant were quantitatively determined using a commercial ELISA kit (MEIMIAN, Shanghai, China). Quantification of viral loads in the tissues DNA was extracted from samples with the DNA Mini Kit (Genstar, Beijing, China) following the instructions. Full-length gE from PRV SH15 DNA was amplified, ligated into pMD19-T to generate the standard plasmid, and quantified. The standard plasmid was 10-fold serially diluted and quantitative PCR (qPCR) with primers gEq-F/gEq-R was performed to generate the standard curve. Viral load in tissues was quantified via gE-targeted qPCR. Histological examination Surviving mice were euthanized on 14 dpc and subjected to systematic autopsy. Brain, lung, and spleen tissues were harvested and fixed with a universal tissue fixative. The samples were subsequently embedded in paraffin, sectioned into cross-sectional slices, stained with hematoxylin and eosin (HE), and analyzed histologically changes. Statistical analysis Data analyses were conducted using a one-way or two-way analysis of variance (ANOVA) using GraphPad Prism version 8.02 (San Diego, CA, USA). p values of < 0.05 were considered statistically significant; p values of < 0.001 were considered extremely significant. All data are presented as mean ± standard error of the mean (SEM) and were obtained from at least three independent experiments. Results Generation of recombinant PRV with deletions in gE, gE/gI and gE/gI/US9 via CRISPR/Cas9 system CRISPR/Cas9 technology was utilized to generate mutant PRV SH15 viruses with targeted deletions of gE, gE/gI, and gE/gI/US9 genes, as shown in Fig. 1. In order to verify the effectiveness of EGFP gene knockout in PRV mutants, we performed indirect immunofluorescence assays (IFA) on four mutants (rPRV ΔgE-EGFP, rPRV ΔgE, rPRV ΔgE/gI, and rPRV ΔgE/gI/US9). The fluorescence signal and cell status were evaluated, and the accuracy of gene deletion was confirmed by PCR. The results demonstrated that only the rPRV ΔgE-EGFP mutant exhibited a green fluorescence signal in the EGFP channel, while no fluorescence signals were detected in the other mutants, confirming the successful knock-out of the EGFP gene. Furthermore, all mutants displayed normal antigen expression in the red channel (Fig. 2A). PCR analysis indicated that the fragment length of the wild type (WT) was 3639 bp, whereas the fragments of the ΔgE, ΔgE/gI, and ΔgE/gI/US9 mutants decreased by approximately 1700 bp, 2800 bp, and 3000 bp, consistent with the expected gene deletion patterns (Fig. 2B). Additionally, gene sequencing results further validated the successful deletion of target genes, providing robust evidence for the efficacy of the gene editing process (Fig. 2C). Collectively, these findings confirm the successful gene deletion and establish a necessary premise for subsequent investigations. Schematic of the construction strategy for PRV SH15 deletions. gE, gE/gI, or gE/gI/US9 gene deletion was achieved by using two sgRNAs to guide Cas9, with EGFP serving as a marker for both positive and negative selection, respectively Construction and identification of three recombinant viruses. A Vero cells were infected with PRV mutants at an MOI of 0.1 at 37 °C. At 24 h post-infection, the cells were fixed, permeabilized, and revealed by polyclonal antibody against PRV (red) and by GFP fluorescence. DAPI was used to stain cell nuclei (blue). B PCR verification of rPRV ΔgE, rPRV ΔgI/gE, and rPRV ΔgE/gI/US9. C The sequencing results of the recombinant virus confirmed the precise deletion of the target sequence and the absence of residual foreign genes Growth characteristics in diverse PRV strains To comprehensively evaluate the replication capacity, growth kinetics, and genetic stability of PRV recombinant strains, this study conducted a systematic analysis of the parental strain PRV SH15 and its recombinants (rPRV ΔgE, rPRV ΔgE/gI, rPRV ΔgE/gI/US9, rPRV ΔgE/gI/US9/US2). Results indicated that the virus titers of rPRV ΔgE, rPRV ΔgE/gI, rPRV ΔgE/gI/US9, rPRV ΔgE/gI/US9/US2 and PRV SH15 were 108.6 TCID50/mL, 108.41 TCID50/mL, 108.3 TCID50/mL, 108.4 TCID50/mL and 108.6 TCID50/mL with no statistically significant differences observed (Fig. 3A). The viral proliferation dynamic curves demonstrated that the replication kinetics of the four gene-deleted viruses were comparable to those of the parental strain PRV SH15. Except for rPRV ΔgE/gI/US9/US2, which exhibited a higher viral titer at 72 h post-infection with a peak titer delayed to 72 h post-infection, the other three recombinant viruses reached peak titers at 48 h post-infection. This observation is also consistent with the previous claim that deletion of US2 enhances viral replication. Minor variations were noted only at 4 h post-infection, where the titers of rPRV ΔgE/gI and rPRV ΔgE/gI/US9 were approximately 101.5 TCID50/mL (Fig. 3B). Plaque assay results indicated that the average plaque diameters formed by rPRV ΔgE, rPRV ΔgE/gI, and rPRV ΔgE/gI/US9 were (0.72 ± 0.11) mm, (0.68 ± 0.09) mm, and (0.58 ± 0.08) mm, which were significantly smaller than that of PRV SH15 (2.01 ± 0.15) mm, P < 0.0001 (Fig. 3C). This suggests that deletion of the gE/gI/US9 genes markedly impaired the virus plaque-forming ability. Genetic stability analysis showed that after 20 consecutive passages of the three recombinant viruses in Vero cells, no sequence reversion or compensatory mutations were detected, indicating their high genetic stability (Fig. 3D). Collectively, these results indicate that deletions of gE/gI/US9 minimally affect viral replication but substantially alter diffusion properties, while maintaining genomic integrity in the recombinants. Biological characterization of different PRV strains. A Viral titer determination was conducted on Vero cells cultured in 96-well plates, quantified using the TCID50 assay. B All recombinant viruses were inoculated onto 6-well plates at a MOI of 0.01. Viruses were harvested at different time points, and viral titers were determined using the TCID50 assay. C Plaque size of recombinant strains versus those of the parental strain PRV SH15 in Vero cells. An asterisk indicates a significant difference. (**** P < 0.0001); ns: not significant. D After 20 consecutive passages of Vero cells during subculture, PCR detection was performed at every fifth passage Evaluation of immune characteristics of recombinant viral vaccines To evaluate the immunogenicity and protective efficacy of the PRV recombinant strains, animal experiments were performed as illustrated in Fig. 4A. Serum analysis revealed that gB specific antibodies became detectable between 7 and 14 dpi, increased progressively, and peaked at 28 dpi before gradually declining, a kinetic profile comparable to that elicited by the commercial vaccine (Fig. 4B). Neutralizing antibody titers against the parental PRV SH15 strain at 21 dpi were 1:49 for rPRV ΔgE, 1:48 for rPRV ΔgE/gI, 1:117 for rPRV ΔgE/gI/US9, and 1:46 for rPRV ΔgE/gI/US9/US2, with similar trends observed against the classical Fa strain. No statistically significant differences were identified among the four recombinant strains, although rPRV ΔgE/gI/US9 showed a relatively higher neutralizing antibody titer. All recombinant strains induced higher neutralizing antibody titers than the commercial vaccine (1:28) (Fig. 4C). Notably, the rPRV ΔgE/gI/US9 strain elicited significantly higher neutralizing antibody responses compared to the other recombinant strains (Fig. 4C). Lymphocyte proliferation assays at 21 dpi showed that the triple-gene deletion (ΔgE/gI/US9) vaccine group induced significantly stronger proliferative responses than the other groups (P < 0.05), indicating a more robust activation of cellular immunity. Furthermore, all tested recombinant strains promoted higher levels of lymphocyte proliferation than the commercial vaccine (Fig. 5A). In conclusion, these results indicate that, among all immunized groups, the three-gene-deleted vaccine elicited the strongest humoral and cellular immune responses. Immunogenicity evaluation of recombinant viruses in mice. A Schematic diagram of the timeline for mouse immunization and challenge. B gB-specific antibody levels were detected in different groups at different times, the ELISA value of the serum sample is expressed by S/N, when S/N is greater than or equal to 0.2, it is positive, and when it is less than 0.2, it is negative. C At 21 dpi, SH15-specific neutralizing antibody and differential neutralizing antibody titers were determined in mouse serum. Statistical significance was denoted as follows: *P < 0.05, ** P < 0.01, and *** P < 0.001 Comparative evaluation of immune responses among different gene-deleted virus strains. A At 21 dpi, mice from different treatment groups (n = 5) were euthanized, and splenocytes were stimulated with Con A and inactivated PRV antigen for 48 h. Lymphocyte proliferation was analyzed using the CCK-8 assay, with results expressed as a Stimulation index (SI). Data are presented as mean ± SEM (n = 5). Asterisks indicate statistically significant differences (* P < 0.05). B At 21 dpi, splenocytes were stimulated with inactivated PRV antigen. After 48 h of incubation, the concentrations of IL-6, IL-4, TNF-α, and IFN-γ in the culture supernatants were quantified using ELISA kits. Data are presented as mean ± SEM (n = 5). Asterisks indicate statistically significant differences (* P < 0.05) Cytokine profiling in immunized groups To evaluate spleen cytokine secretion in mice from different groups, spleen cells were isolated, stimulated with inactivated PRV antigen for 48 h, and supernatant concentrations of IL-6, IL-4, TNF-α, and IFN-γ were measured. Results demonstrated that no significant differences in IL-6 levels were observed among the immunized groups (Fig. 5B). The IL-4 concentration was highest in the rPRV ΔgE group, significantly exceeding those in the rPRV ΔgE/gI, rPRV ΔgE/gI/US9, and rPRV ΔgE/gI/US9/US2 groups (P < 0.01). Notably, the levels of TNF-α and IFN-γ peaked in the rPRV ΔgE/gI/US9 group. Specifically, TNF-α levels in this group were significantly higher than those in the rPRV ΔgE/gI/US9/US2 group (P < 0.05) and the rPRV ΔgE/gI group (P < 0.01). Furthermore, the IFN-γ level in the rPRV ΔgE/gI/US9 group was extremely significantly higher compared to the rPRV ΔgE/gI/US9/US2 group (P < 0.0001) and highly significantly higher compared to the rPRV ΔgE/gI group (P < 0.01). These findings suggest that recombinant strains, particularly rPRV ΔgE/gI/US9, markedly enhance the secretion of Th1-type cytokines (TNF-α and IFN-γ), effectively promoting cellular immune responses. This provides a critical reference for elucidating the immune regulatory mechanisms underlying PRV vaccine development. Evaluate the protective efficacy of recombinant viral vaccines In order to evaluate the protective efficacy of different gene-deleted PRV strains, mice were subjected to challenge and monitored for survival, body weight changes, and viral loads in brain and lung tissues at 14 days post-challenge (dpc). All vaccinated groups (rPRV ΔgE, rPRV ΔgE/gI, rPRV ΔgE/gI/US9, rPRV ΔgE/gI/US9/US2) achieved 100% survival throughout the observation period, whereas the challenge positive control group showed 0% survival. This complete protection exceeded the 80% survival rate reported for the commercial inactivated vaccine (Fig. 6A). Body weight fluctuations in vaccinated mice were minimal and comparable to those in the commercial vaccine group, whereas unvaccinated mice exhibited significant weight loss (Fig. 6B). Furthermore, viral load analysis further demonstrated the efficacy of the recombinant vaccines. In brain tissue, although the rPRV ΔgE group showed a slightly higher viral load than the other vaccine groups, all vaccinated groups displayed similar viral loads to the commercial vaccine group and significantly lower than the DMEM control (P < 0.0001) (Fig. 6C). In lung tissue, all vaccine groups had significantly lower viral loads than the PRV SH15 challenged group (P < 0.0001) (Fig. 6C). These results indicate that multi-gene-deleted PRV vaccines provide complete protection against lethal challenge and effectively suppress viral replication in key target tissues. Protection efficiency analysis of different gene-deleted virus strains. A Survival rate of mice immunized with recombinant virus was challenged with 105 TCID50 (100× LD50) of the SH15 strain. Detailed results of the LD50 determination are shown in Fig. S1. B Body weight changes in mice within 120 h post SH15 challenge, monitored every 12 h. C Fourteen days after the virus challenge, the mice were euthanized. Brain, lung and spleen tissues (0.1 g) were collected respectively, and the viral load in the tissues was quantitatively detected by qPCR Histological examination After the conclusion of the viral challenge protection experiment, all surviving mice were humanely euthanized, and their tissues and organs were harvested for further analysis. Gross pathological examination revealed that mice in the positive control group exhibited marked cerebral hemorrhage and severe pulmonary hemorrhage (Fig. 7A). Subsequent HE staining further confirmed extensive tissue damage in the infected group (Fig. 7B). Specifically, the brain showed significant neuronal atrophy (black arrow), while the lung exhibited both scattered granulocyte infiltration in alveolar walls (black arrow) and slight eosinophilic mucus secretion in bronchiolar lumens (red arrow) (Fig. 7B). The spleen also displayed diffuse lymphocyte necrosis in the white pulp (red arrow) (Fig. 7B). Conversely, mice in the vaccine protection group displayed no apparent gross tissue damage, and HE staining results showed no notable histopathological abnormalities (Fig. 7). Gross pathological changes and histopathological lesions in immunized mice following PRV SH15 challenge. A Gross pathological changes of mouse tissues including brain, lung and spleen at 14 dpc. B Histopathological lesions in the corresponding tissues observed by HE staining (200× magnification) Discussion PR is an acute and highly lethal infectious disease caused by the PRV. While PRV can affect pigs of any stage of life [16], the spectrum and severity of symptoms largely depend on the age and physiological condition of the host [17]. Newborn piglets typically present with fever, severe neurological disorders, and respiratory distress, often resulting in high mortality [18]. In pregnant sows, infection can lead to abortion and the delivery of mummified fetuses [19], while breeding boars may experience infertility [20]. PRV also exhibits a broad host tropism, capable of infecting a range of species including cattle, sheep, rabbits, mice, cats, dogs [21–25]. Notably, human infections, though rare, have been documented with over 26 cases reported as of January 2023 [26]. Vaccination remains the primary strategy of PR prevention and control. However, since 2011, outbreaks have persisted in swine populations despite widespread use of the Bartha-K61 vaccine [27]. Genomic analyses indicate that current prevalent PRV variants carry multiple genetic alterations, including substitutions, insertions, and deletions [28], compared to classical strains, which are associated with enhanced viral virulence and lethality [29]. Consequently, traditional vaccines no longer confer complete immune protection [30]. Current prevention and control strategies mainly rely on both attenuated and inactivated vaccines. While attenuated vaccines generally induce a robust immune response, they carry the potential risk of recombination with wild-type strains, which could lead to more virulent outbreaks. In contrast, inactivated vaccines offer higher safety profile with no such recombination risk, though they often exhibit comparatively lower immunogenicity [31]. In response, HDR-CRISPR/Cas9 technology was employed to design and construct a panel of PRV mutants with successively expanded deletions in key virulence and neuroinvasion associated genes (gE, gI, US9, and US2), aiming to develop a superior inactivated vaccine candidate. In this study, we assessed the immunogenicity of inactivated vaccines derived from PRV variant with various gene deletions. Among all constructed mutants, the triple-gene deletion strain demonstrated superior immunogenicity, eliciting higher levels of neutralizing antibodies, enhanced cytokine secretion, and stronger lymphocyte proliferation compared to other variants. PRV has a large genome that encodes numerous non-essential proteins for viral replication, including gI, gE, US9, and US2. The glycoproteins gE and gI, known as major virulence factors of PRV, typically function as a heterodimeric complex. Their deletion not only significantly attenuates viral pathogenicity but also provides a basis for differentiating infected from vaccinated animals (DIVA) [32], supporting disease control and eradication programs. In contrast, the US9 protein plays a critical role in anterograde axonal transport of PRV, while deletion of US2 has been reported to enhance viral replication and virulence. To achieve precise genomic editing, we employed the CRISPR/Cas9 system combined with HDR technology. Initially, the gE gene was replaced with an EGFP cassette, generating the recombinant virus rPRV ΔgE-EGFP. Subsequently, specific sgRNAs were designed to target and excise the EGFP tag, yielding recombinant viruses free of exogenous sequences. Based on the same approach, three distinct recombinant viruses were further developed (Fig. 1). This strategy enabled highly efficient editing without introducing foreign genetic elements, thereby circumventing limitations associated with the Cre/LoxP system, such as residual LoxP sites that may cause genomic instability or unintended immunogenicity. The identities of all recombinant viruses were confirmed through IFA, PCR, and sequencing (Fig. 2). Viral titers and growth kinetics of the mutant strains were comparable to those of the wild-type virus, indicating that the deletions did not impair replication efficiency. However, a marked reduction in plaque size was observed, consistent with attenuated cell-to-cell spread capacity, which is critical for herpesviruses latent infection and reactivation. Furthermore, the genetic stability of the deletion mutants was verified over 20 consecutive passages, with no evidence of sequence restoration or recombination (Fig. 3). To systematically evaluate the immunogenicity of various gene-deletion strains, we monitored the dynamics of gB specific antibody levels over 35 dpi and measured neutralizing antibody titers at 21 and 35 dpi in a mouse model. The results demonstrated that a positive gB antibody response was detectable as early as 14 dpi, and neutralizing antibody titers ranged from 1:32 to 1:128 by 21 dpi. Neutralization assays against the classical PRV Fa strain further confirmed th IL-4 and IL-6 are primarily participate e induction of robust cross-protective immunity across these vaccine candidates. Notably, the rPRV ΔgE/gI/US9 strain elicited the highest neutralizing antibody titer of up to 1:128, indicating its superior immunogenicity (Fig. 4). Neutralizing antibody levels are critical for pathogen clearance, while cellular immune responses also play an essential role in the overall immune defense [33]. Lymphocyte proliferation is a key indicator of cellular immune activation [34]. To evaluate the effect of different vaccine strains on cellular immunity, we isolated and stimulated mouse splenocytes with either Con A or PRV antigens, and assessed their proliferative capacity. Our findings revealed that, on 21 dpi, splenocytes from mice immunized with rPRV ΔgE/gI/US9 exhibited significantly stronger proliferation compared to those receiving other deletion strains, suggesting a more potent activation of T-cell-mediated immunity (Fig. 5). We further analyzed cytokine profiles to characterize the nature of the cellular immune response. IFN-γ, a pivotal cytokine in antiviral defense, promotes the activation of cytotoxic T lymphocytes and natural killer cells [35], and recruits macrophages to infection sites [36]. TNF-α enhances the Th1 response and stimulates macrophages-mediated pathogen clearance [37]. Both IFN-γ and TNF-α are central mediators of the Th1-type immunity, which is critical for controlling intracellular infections [38]. In contrast, IL-4 and IL-6 primarily participate in the Th2-type immune response [39], which target extracellular pathogens and support B-cell antibody production [40]. This study demonstrated that the rPRV ΔgE/gI/US9 vaccine significantly enhanced Th1-type immune response, as evidenced by elevated IFN-γ and TNF-α levels, whereas no marked differences were observed in Th2-associated cytokine responses (Fig. 5). In comparison with gE single- or gE/gI double-deleted viruses, it is hypothesized that the gE/gI/US9 triple-deletion leads to greater attenuation of virulence and may affect the expression or structural integrity of other viral proteins, including critical envelope antigens like gB, gC, and gD. However, the inactivated vaccine derived from this triple-deleted virus is believed to present a more complete antigenic repertoire to the host immune system. This facilitates the recognition of diverse protective epitopes, enabling the generation of a more robust and broadly reactive neutralizing antibody response. In challenge experiments, mice were exposed to a viral dose exceeding 100 times of the LD₅₀. All immunized mice survived without significant body weight loss. Moreover, viral loads in both brain and lung tissues were substantially reduced following challenge (Fig. 6), underscoring the protective efficacy of the vaccine candidates, particularly the rPRV ΔgE/gI/US9 group. We hypothesized that variations in immune responses elicited by different recombinant PRV strains could arise from altered expression levels of key viral antigens. To test this, relative quantitative PCR (qPCR) was performed to assess the gene expression of two major antigens, gB and gD. Results indicated that gD gene expression was significantly lower in the rPRV ΔgE strain than in other groups, while gB expression was notably reduced in the rPRV ΔgE/gI/US9/US2 strain. No significant differences in gB or gD expression were detected in the remaining two recombinant strains (Fig S2). These data suggest that specific gene deletions may modulate viral antigen expression, contributing to differential immunogenicity. Further studies should assess whether these deletions alter gB, gD and other viral proteins expression, clarifying how genetic modifications influence antigen presentation and subsequent immune responses. In summary, this study successfully constructed a series of PRV SH15-derived strains with single(ΔgE), double(ΔgE/gI), and triple(ΔgE/gI/US9) gene deletions, and systematically evaluated their biological characteristics and immunogenicity in a mouse model. All deletion strains exhibited comparable growth kinetics and proliferation comparable to those of the parental virus in vitro. Notably, the triple-deletion strain rPRV ΔgE/gI/US9 elicited a stronger immune response than those deletion variants and a commercial vaccine. A limitation of this study is that only a single immunization dose of 107 TCID50 was employed without evaluating dose-dependent effects. Additional limitations include the relatively short observation period for immune persistence, unclear long-term protective efficacy, insufficient large-scale safety evaluations in target animals such as pigs, and unvalidated cross-protection against heterologous PRV strains. This dose was selected based on its common use in commercial vaccines and relevant literature reporting no significant differences in protection across similar dose ranges in mice; these limitations will be systematically addressed in follow-up research. Future work should assess the protective efficacy of rPRV ΔgE/gI/US9 strain in pigs, as well as optimizing adjuvant formulations and exploring the underlying immunological mechanisms. Collectively, these results indicate that the extent of gene deletion may modulate vaccine immunogenicity, offering valuable guidance for the rational design of gene-deleted vaccines. Supplementary Information Supplementary Material 1: Fig S1. Determination of LD50 of parental PRV SH15 and four gene-deleted mutant strains in mice. (A) Parental PRV SH15 strain; (B–E) rPRV ΔgE, rPRV ΔgE/gI, rPRV ΔgE/gI/US9 and rPRV ΔgE/gI/US9/US2 mutant strains. Each strain was serially diluted from 102 to 106 TCID₅₀ and used to challenge mice, and the median lethal dose (LD50) was subsequently calculated. Supplementary Material 2: Fig S2. Detection of gB and gD mRNA expression levels in PK15 cells infected with parental and gene-deleted PRV strains. (A) Relative mRNA transcription level of gB gene; (B) Relative mRNA transcription level of gD gene. PK15 cells were infected with parental PRV SH15, rPRV ΔgE, rPRV ΔgE/gI, rPRV ΔgE/gI/US9, and rPRV ΔgE/gI/US9/US2 strains, respectively. At 24 h post-infection, the relative mRNA transcription levels were determined by real-time quantitative PCR (RT-qPCR) with GAPDH as the internal reference gene. Supplementary Material 3. Supplementary Material 4. Supplementary Material 5. Supplementary Material 6. Acknowledgements We would like to thank all participants for their help in the research. Abbreviations Analysis of Variance Base Pair β-Propiolactone CRISPR-Associated Protein-9 Cell Counting Kit-8 Carbon Dioxide Concanavalin A Cytopathic Effect Clustered Regularly Interspaced Short Palindromic Repeats Days Post Challenge Days Post Immunization Dulbecco's Modified Eagle Medium Differentiating Infected from Vaccinated Animals Enzyme-Linked Immunosorbent Assay Enhanced Green Fluorescent Protein Fetal Bovine Serum Figure Glycoprotein B Glycoprotein C Glycoprotein D Glycoprotein E Glycoprotein I Homology-Directed Repair Hematoxylin and Eosin Interferon-γ Interleukin-4 Interleukin-6 International ISA206 Adjuvant Kunming mice Lethal Dose 50 Multiplicity of Infection Milligram Milliliter Microliter Microgram Not Significant Optical Density Phosphate-Buffered Saline Polymerase Chain Reaction Pseudorabies Pseudorabies Virus Quantitative Polymerase Chain Reaction Recombinant Pseudorabies Virus Revolutions Per Minute Standard Error of the Mean Single-Guide RNA Stimulation Index Specific Pathogen-Free 50% Tissue Culture Infectious Dose Tumor Necrosis Factor-α Thymidine Kinase Unique Long 13 Unique Long 16 Unique Short 2 Unique Short 8 Unique Short 9 Degree Celsius Volume per Volume Authors’ contributions B L, K Z and Y Z: Supervision, Project administration. W Z, J T and W Y: Writing – review & editing, Visualization, Supervision, Resources, Project administration, Funding acquisition. Y Yang and Z X: Methodology, Software, Formal analysis, Writing – review & editing. H Z and Z Y: Investigation, Conceptualization. All authors have read and agreed to the published version of the manuscript. Funding This research was funded by Science Research Project of Hebei Education Department (Grant NO. QN2024288) and Natural Science Foundation of Hebei Province (Grant NO. C2024204069, C2025201053). The funders were not involved in study design, data collection, interpretation, or the decision to submit this work for publication. Data availability The datasets of PRV SH15 strain are available in the NCBI (GenBank accession No. PV360712.1). All data supporting the findings of this study are available from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate All animal studies were conducted in strict compliance with animal welfare guidelines and approved by the Hebei Agricultural University’s Ethics Committee (2024045) (approval date: 28 Feb 2024). Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Yuchuan Yang and Ziyun Xie contributed equally to this work. Contributor Information Wanzhe Yuan, Email: yuanwanzhe@hebau.edu.cn. Jie Tong, Email: tongjie2019@hbu.edu.cn. Wuchao Zhang, Email: zhangwc@hebau.edu.cn. References Associated Data Supplementary Materials Supplementary Material 1: Fig S1. Determination of LD50 of parental PRV SH15 and four gene-deleted mutant strains in mice. (A) Parental PRV SH15 strain; (B–E) rPRV ΔgE, rPRV ΔgE/gI, rPRV ΔgE/gI/US9 and rPRV ΔgE/gI/US9/US2 mutant strains. Each strain was serially diluted from 102 to 106 TCID₅₀ and used to challenge mice, and the median lethal dose (LD50) was subsequently calculated. Supplementary Material 2: Fig S2. Detection of gB and gD mRNA expression levels in PK15 cells infected with parental and gene-deleted PRV strains. (A) Relative mRNA transcription level of gB gene; (B) Relative mRNA transcription level of gD gene. PK15 cells were infected with parental PRV SH15, rPRV ΔgE, rPRV ΔgE/gI, rPRV ΔgE/gI/US9, and rPRV ΔgE/gI/US9/US2 strains, respectively. At 24 h post-infection, the relative mRNA transcription levels were determined by real-time quantitative PCR (RT-qPCR) with GAPDH as the internal reference gene. Supplementary Material 3. Supplementary Material 4. Supplementary Material 5. Supplementary Material 6. Data Availability Statement The datasets of PRV SH15 strain are available in the NCBI (GenBank accession No. PV360712.1). All data supporting the findings of this study are available from the corresponding author upon reasonable request.